id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2009-P-0595-0007,FDA,FDA-2009-P-0595,"Attachment B - ""Meridia (Sibutramine) United States Food and Drug Administration Endocrinologic and Metabolic Drug Advisory Committee Meeting on September 15, 2010"" - [Abbott Laboratories, Inc. - Comment]",Supporting & Related Material,C-Comment (Supporting and Related Material),2011-01-28T05:00:00Z,2011,1,,,2011-01-28T21:21:32Z,,0,0,0900006480b61f7c
FDA-2009-P-0595-0006,FDA,FDA-2009-P-0595,"Attachment A - ""Advisory Committee Briefing Document for Meridia (Sibutramine HydrochloridemMonohydrate) Endocrinologic and Metabolic Drug Advisory Committee Meeting on September 15, 2010"" - [Abbott Laboratories, Inc. - Comment]",Supporting & Related Material,C-Comment (Supporting and Related Material),2011-01-28T05:00:00Z,2011,1,,,2011-01-28T21:20:58Z,,0,0,0900006480b61f7a
FDA-2009-P-0595-0005,FDA,FDA-2009-P-0595,FDA/CDER to Public Citizen's Health Research Group -  Petition Approval,Other,PAV-Petition Approval,2011-01-05T05:00:00Z,2011,1,2011-01-05T05:00:00Z,,2013-08-11T01:39:06Z,,0,0,0900006480bc55ae